TitleDate
SATELLOS Announces Q3 2022 Financial Results and Operational HighlightsNovember 23, 2022
SATELLOS Announces Advancement of Compounds to Next Stage of DevelopmentNovember 3, 2022
SATELLOS to present preliminary preclinical proof of concept data for an additional rare disease at World Muscle Society Meeting October 11, 2022
SATELLOS INC. Announces Licensing of Formulation Technology and Expand Collaboration with NW PHARMATECH LTD.October 6, 2022
SATELLOS Announces OTCQB Listing in the United StatesOctober 6, 2022
SATELLOS Announces the Appointment of Philip D. Lambert, Ph.D, as  Chief Technology OfficerSeptember 28, 2022
SATELLOS Announces Closing of Offering of UnitsSeptember 13, 2022
SATELLOS Announces the Filing of Final Short Form Prospectus for Proposed Offering of UnitsSeptember 7, 2022
SATELLOS Announces Pricing of Proposed Offering of Units August 31, 2022
SATELLOS Reports Q2 2022 Financials and Operating ResultsAugust 29, 2022
SATELLOS Announces the Filing of an Amended and Restated Preliminary Prospectus for Proposed Offering of UnitsAugust 29, 2022
SATELLOS Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Published in Nature CommunicationsJuly 13, 2022
SATELLOS Announces Proposed Offering of UnitsJuly 11, 2022
SATELLOS Announces In-Licensing of New Patent ApplicationJune 30, 2022
SATELLOS Co-Founder and Chief Scientific Officer Dr. Michael Rudnicki Officially Recognized as a Fellow of the Royal SocietyJune 22, 2022
SATELLOS Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 GrantJune 17, 2022
 SATELLOS to present at Bio International Convention 2022 June 14, 2022
SATELLOS to Present at the LD Micro InvitationalJune 1, 2022
SATELLOS Announces Q1 2022 Results and Operational HighlightsMay 31, 2022
 SATELLOS Announces 2021 Year End Financial Results and Operational HighlightsMay 2, 2022
SATELLOS to Present at the 2022 Bloom Burton & CO. Healthcare Investor Conference 2022April 26, 2022
SATELLOS to Present at Upcoming European Molecular Biology Organization WorkshopApril 21, 2022
SATELLOS to Present at Upcoming Game Changing Science During March 30 Drug Discovery News WebinarMarch 29, 2022
SATELLOS Provides Update on Novel Regenerative Drug CandidatesMarch 15, 2022
SATELLOS Provides Update on Joint Development Initiative with NW PharmaTech Limited March 11, 2022
SATELLOS to Present Game Changing Science at Insights In Research Investor Summit and MDA Clinical & Scientific Conference 2022March 10, 2022
SATELLOS to Participate at BIO CEO & Investor Conference 2022February 10, 2022
Shareholder Letter from CEOJanuary 24, 2022
SATELLOS to participate at BIOTECH SHOWCASE™ Virtual 2022January 10, 2022
SATELLOS Announces Research Agreement with Université De Sherbrooke to Study Rare Muscular DystrophiesDecember 16, 2021
SATELLOS Announces New Board AppointmentsDecember 6, 2021
SATELLOS Reports Third Quarter 2021 Financial Results and Operational HighlightsNovember 29, 2021
SATELLOS Retains BND Projects Inc. for Strategic Investor Relations ServicesOctober 26, 2021
SATELLOS Announces Appointment of J. Robert Hall as Vice-President, Finance and AdministrationSeptember 17, 2021
SATELLOS Announces Evidence for Regeneration in Severe Model of DuchenneSeptember 13, 2021
SATELLOS Announces Second Quarter 2021 Financial Results and MD&AAugust 30, 2021
SATELLOS Announces High Resolution Crystal Structure of Duchenne Drug TargetAugust 26, 2021
SATELLOS Announces Partnership with Jesse’s JourneyAugust 25, 2021
SATELLOS Announces Joint Development Agreement with NW PharmaTech Limited for Oral CBDAugust 18, 2021
SATELLOS and iCo Announce Completion of Reverse TakeoverAugust 13, 2021
iCo Therapeutics Inc. Announces Shareholder Approval of business combination with Satellos Bioscience Inc.August 5, 2021
iCo Therapeutics Inc. Announces TSX Venture Exchange Conditional Approval and Provides Update regarding Business Combination with Satellos Bioscience Inc.July 8, 2021
iCo Therapeutics Subsidiary to present Oral Amphotericin B / SARS-Cov-2 Research Results at National Pharmaceutical Sciences MeetingMay 10, 2021
iCo Therapeutics Announces 2020 Year End Financial Results and Resignation of Susan KoppyApril 29, 2021
iCo Therapeutics Inc. Announces Closing of Upsized Subscription Receipt Private PlacementApril 27, 2021
iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private PlacementApril 22, 2021
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.March 22, 2021
iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2March 15, 2021
iCo Therapeutics Inc. Announces Warrant ExercisesMarch 11, 2021
iCo Therapeutics Inc. Proposes to Re-Price WarrantsJanuary 11, 2021
iCo Therapeutics Announces Joint Development of iCo-019 with Skymount MedicalDecember 31, 2020
iCo Therapeutics Announces Third Quarter 2020 Financial ResultsNovember 24, 2020
iCo Therapeutics Announces Option GrantsOctober 26, 2020
iCo Therapeutics Inc. Announces That Oral Amphotericin B (iCo-019) Results Will Be Highlighted During the American Association of Pharmaceutical Scientists (AAPS) Virtual Meeting October 26 – November 3rd, 2020October 21, 2020
iCo Therapeutics Announces Second Quarter 2020 Financial ResultsAugust 31, 2020
iCo Therapeutics Inc. Announces Publication of Oral Amphotericin B (iCo 019) Phase 1 Safety Study Results in Prestigious Infectious Diseases JournalJuly 30, 2020